Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced management participation in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced management participation in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The company is focused on developing treatments for complex rare diseases, particularly its lead compound CTI-1601, which is undergoing a Phase 1 clinical program for Friedreich's ataxia. Larimar aims to leverage its intracellular delivery platform to create new fusion proteins for additional rare diseases.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was +2.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29, 2021 through December 2, 2021.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.